Sanofi-BioLabs Golden Ticket Competition: call for applications from health startups

In partnership with BioLabs, Sanofi has announced the launch of a new Global Golden Ticket Competition that will award a promising young company with a one-year prepaid residence at BioLabs Hôtel-Dieu in Paris.

The scope of this new global Golden Ticket 2023 is to promote the emergence of innovative therapeutic and technological approaches for the treatment of chronic inflammatory diseases and/or to modulate neuronal inflammation pathways, and more specifically:

• New immunological therapies for chronic inflammatory diseases (including enabling technologies and precision medicine approaches), e.g. those capable of regulating mechanisms that induce tolerance and restore immune homeostasis, activation of inhibitory immune checkpoints, multi-target cytokine therapies and antigen-specific therapies.

• New disease-modifying therapies targeting the neuroinflammation pathways for neurological and neurodegenerative disorders, including progressive multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Alzheimer's disease.

Any interested startups that are active in these fields are encouraged to apply by February 10, 2023 to be eligible. A complete application file and non-confidential presentation must be submitted in accordance with the terms and conditions detailed on the official Golden Ticket site indicated below.

Link to the official announcement

Link to the official site to submit your Golden Ticket application